Low dose aspirin in the prevention of recurrent spontaneous preterm labour - the APRIL study: a multicenter randomized placebo controlled trial

Preterm birth (birth before 37 weeks of gestation) is a major problem in obstetrics and affects an estimated 15 million pregnancies worldwide annually. A history of previous preterm birth is the strongest risk factor for preterm birth, and recurrent spontaneous preterm birth affects more than 2.5 mi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC Pregnancy and Childbirth 2017-07, Vol.17 (1), p.223-223, Article 223
Hauptverfasser: Visser, Laura, de Boer, Marjon A, de Groot, Christianne J M, Nijman, Tobias A J, Hemels, Marieke A C, Bloemenkamp, Kitty W M, Bosmans, Judith E, Kok, Marjolein, van Laar, Judith O, Sueters, Marieke, Scheepers, Hubertina, van Drongelen, Joris, Franssen, Maureen T M, Sikkema, J Marko, Duvekot, Hans J J, Bekker, Mireille N, van der Post, Joris A M, Naaktgeboren, Christiana, Mol, Ben W J, Oudijk, Martijn A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Preterm birth (birth before 37 weeks of gestation) is a major problem in obstetrics and affects an estimated 15 million pregnancies worldwide annually. A history of previous preterm birth is the strongest risk factor for preterm birth, and recurrent spontaneous preterm birth affects more than 2.5 million pregnancies each year. A recent meta-analysis showed possible benefits of the use of low dose aspirin in the prevention of recurrent spontaneous preterm birth. We will assess the (cost-)effectiveness of low dose aspirin in comparison with placebo in the prevention of recurrent spontaneous preterm birth in a randomized clinical trial. Women with a singleton pregnancy and a history of spontaneous preterm birth in a singleton pregnancy (22-37 weeks of gestation) will be asked to participate in a multicenter, randomized, double blinded, placebo controlled trial. Women will be randomized to low dose aspirin (80 mg once daily) or placebo, initiated from 8 to 16 weeks up to maximal 36 weeks of gestation. The primary outcome measure will be preterm birth, defined as birth at a gestational age (GA) 
ISSN:1471-2393
1471-2393
DOI:10.1186/s12884-017-1338-0